RECRUITING

RH Genotype Matched RBC Transfusions

Conditions

Sickle Cells Disease Chronic Transfusion

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

Official Title

RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease

Quick Facts

Study Start:2020-01-30

Study Completion:2029-10

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04156893

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Months

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subjects age \>6 months * Diagnosis of SCD, all genotypes * Require a period of chronic red cell transfusion therapy * Subject/parental/guardian permission (informed consent) and if appropriate, child assent	* Rare RH genotype that would preclude identification of sufficient RBC units * Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units * Alloimmunized to D antigen * Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols * Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures

Inclusion Criteria

Exclusion Criteria

* Subjects age \>6 months
* Diagnosis of SCD, all genotypes
* Require a period of chronic red cell transfusion therapy
* Subject/parental/guardian permission (informed consent) and if appropriate, child assent

* Rare RH genotype that would preclude identification of sufficient RBC units
* Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units
* Alloimmunized to D antigen
* Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols
* Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures

Contacts and Locations

Study Contact

Stella Chou, MD

CONTACT

215-590-0947

chous@chop.edu

Principal Investigator

Stella Chou, MD

PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Study Locations (Sites)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

United States

Collaborators and Investigators

Sponsor: Children's Hospital of Philadelphia

Stella Chou, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-30

Study Completion Date2029-10

Study Record Updates

Study Start Date2020-01-30

Study Completion Date2029-10

Terms related to this study

Keywords Provided by Researchers

Chronic Transfusion

Additional Relevant MeSH Terms

Sickle Cells Disease